Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc. (CYTH) Stock Overview
Explore Cyclo Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
23.6M
P/E Ratio
-0.59
EPS (TTM)
$-0.90
ROE
-7.30%
CYTH Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Cyclo Therapeutics, Inc. (CYTH) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.59 and a market capitalization of 23.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.